Substantia Nigra MRI markers are lower in Alzheimer's disease and are linked to novelty and memory
Friedrich Krohn,Mousumi Sarkar,Hartmut Schuetze,Panagiotis Iliopoulos,Lucua Penalba-Sanchez,Dorothea Haemmerer,Renat Yakupov,Falk Luesebrink,Annika Spottke,Anja Schneider,Nina Roy-Kluth,Enise Incesoy,Michael Heneka,Ingo Kilimann,Luca Kleineidam,Stefan Teipel,Frederik Brosseron,Doreen Goerss,Wenzel Glanz,Matthias Schmid,Ayda Rostamzadeh,Michael Wagner,Klaus Fliessbach,Frank Jessen,Emrah Duezel,Matthew Betts
DOI: https://doi.org/10.1101/2024.10.19.24315797
2024-10-21
Abstract:Individuals with Alzheimer′s disease dementia postmortem show Alzheimer′s disease pathology in and heterogeneous degeneration of the Substantia Nigra (SN). However, it is unclear how the SN degeneration is related to cognitive dysfunction across the Alzheimer′s disease dementia continuum. In this study, using data from a prospective dementia study (DELCODE), we investigated if in-vivo SN MRI measures are lower in cases with clinically defined Alzheimer′s disease dementia than in healthy control subjects (HC) and if they are associated with functional activity during the processing of novel visual stimuli and subsequent recognition memory.
161 DELCODE participants (69 years ±6 years, 88 men), including 79 HC, 71 individuals with subjective cognitive impairment (SCD), 17 individuals with mild cognitive impairment (MCI), and 10 individuals with Alzheimer′s disease dementia, completed a scene novelty and encoding task and a 3T neuromelanin (NM)-sensitive MRI scan, from which the two in-vivo SN measures MRI contrast and volume were calculated. For 71 individuals, CSF levels of phospoTau, total tau, and amyloid beta 42/40 ratio (Aβ42/40) were available. All individuals completed a neuropsychological task battery from which a global cognitive score was calculated.
SN volume but not SN MRI contrast was lower in individuals with clinical Alzheimer′s disease dementia (One-way ANCOVA; F(3,156)=4,13, N=160, p=0.001). SN MRI contrast and volume were not associated with Aβ42/40, ptau, and ttau CSF levels (all p<0.1). SN MRI contrast was positively associated with anterior hippocampal functional activity during the presentation of novel stimuli in individuals with Aβ42/40 ratio levels below a pathological threshold of 0.08 (Aβ42/40 positive, p(FWE)=0.002, 157 voxels, n=28) but not in Aβ42/40 negative individuals. Moreover, SN volume was positively associated with recognition memory (N=160, p=0.017, r2=0.11) and global cognition (p<0.0001, N=160, r2=0.221) across the Alzheimer′s disease dementia continuum.
Our study emphasizes the potential of using in-vivo SN MRI markers to understand the impact of Alzheimer′s disease pathology-independent SN degeneration on recognition memory and novelty processing dysfunction in Alzheimer′s disease dementia. Our results motivate future longitudinal studies exploring how SN volume and SN contrast change over time, how these are differentially associated with cognitive decline, and how the SN volume and SN contrast might be associated with other dopamine-dependent cognitive functions.
Neurology